Efavirenz intoxication due to slow hepatic metabolism

被引：51

作者：

Hasse, B ^{[1
]}

Günthard, HF

Bleiber, G

Krause, M

机构：

[1] Cantonal Hosp Munsterlingen, Dept Internal Med, CH-8596 Munsterlingen, Switzerland

[2] Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland

[3] Univ Lausanne Hosp, Div Infect Dis & Hosp Epidemiol, Lausanne, Switzerland

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 40卷 / 03期

关键词：

D O I：

10.1086/427031

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We describe a human immunodeficiency virus-positive woman who presented with severe psychosis while she was receiving therapy with efavirenz. Her plasma efavirenz level was excessively high. Genetic investigation showed that she was homozygous for the CYP2B6 G516T allele, resulting in slow hepatic metabolism. After the dosage of efavirenz was lowered, all neuropsychiatric symptoms subsided.

引用

页码：E22 / E23

页数：2

共 14 条

[11] Stähle L, 2004, THER DRUG MONIT, V26, P267, DOI 10.1097/00007691-200406000-00008
[12] Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens
Tsuchiya, K
Gatanaga, H
Tachikawa, N
Teruya, K
Kikuchi, Y
Yoshino, M
Kuwahara, T
Shirasaka, T
Kimura, S
Oka, S
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 319 (04) : 1322 - 1326
[13] The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
Ward, BA
Gorski, JC
Jones, DR
Hall, SD
Flockhart, DA
Desta, Z
[J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (01) : 287 - 300
[14] 2002, SUSTATIVA EFAVIRENZ

← 1 2 →